India Pharma Outlook Team | Friday, 26 September 2025
India and Mexico have opened up strategic talks that focus on expanding the Indian pharmaceutical industry's opportunities. The communication is designed to provide better access to cheaper drugs in Mexico, to promote the mutual recognition of the Indian Pharmacopoeia (IP) and to support investments in clinical research.
Records of the discussions are that the Consulate of Mexico in Mumbai organized it in collaboration with the Pharmaceuticals Export Promotion Council of India (Pharmexcil). The talks focused on trade expansion and regulatory harmonization. India is thanked for the offer of better access to the market, which could facilitate overcoming of regulatory barriers and also enabling more sectoral collaboration.
Pharmexcil Director Murali Krishna mentioned that Mexico represents the Latin American and the Caribbean's largest pharmaceutical market for which the value in 2024 was $17.2 billion, with imports worth $6.5 billion. India’s pharma exports to Mexico were $320 million in 2023.
New Delhi pharma companies have been invited to invest in domestic production under the “Made in Mexico” initiative. Sergio Silva from Mexico’s Ministry of Economy gave an overview of the country's industrial policies, incentives for R&D, and a 2030 vision focusing on reaching $2 billion annual investment in clinical research and a 15% increase in pharma manufacturing.
Also Read: Alembic Pharma Gets USFDA Nod for Paroxetine ER Tablets
They also spoke about the simplification of regulations, the opportunities that exist in the field of biosimilars and generics, and the joint efforts to obtain health self-sufficiency through the production of vaccines and generics for critical diseases.
